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Abstract
Background: The value of qualitative methods within trials is widely recognised, but their full potential is not being
realised. There are also issues with the visibility, recognition and reporting of qualitative methods in trials. To identify
potential improvements in qualitative research within trials, we need to study trials that have included qualitative
methods. We aimed to explore the frequency of reporting qualitative methods in registered trials, the types of trials
using qualitative methods and where in the world these trials were conducted.
Methods: We included registries if they were searchable using keywords and held summaries of trials rather than listing
reports or publications. We searched the included registries from the first available record in 1999 to the end of 2016 for
the term ‘qualitative’. We included trials only if we could confirm that they used qualitative methods through
documented use of qualitative data collection and analysis in the registry summary. We analysed registered
trials reporting the use of qualitative methods by: year registered, the country responsible for overseeing governance
of the trial and the type of trial intervention (categorised as surgical, medical device, behavioural, drug or other).
Results: We included three registries: ClinicalTrials.gov, the International Standard Randomised Controlled Trial Number
Registry (ISRCTN) and the World Health Organisation International Clinical Trials Registry Platform (WHO ICTRP). A total
of 615,311 trials appear in these three registries from 1999 until the end of 2016. Numbers differed across registries
with the WHO ICTRP the largest (366,753 trials), ClinicalTrials.gov the second largest (233,277) and ISRCTN the smallest
(15,301). Of these registered trials, we confirmed that 1492 (0.24%) reported using qualitative methods. The ISRCTN
contributed the highest percentage of trials reported as using qualitative methods (3.4%); in contrast, ClinicalTrials.gov
reported 0.3% and WHO ICTRP reported 0.03%. The number and percentage of trials reported to use qualitative methods
increased over time from 0 (0.0%) in 1999 to 285 (0.38%) in 2016. Trials reported as using qualitative methods originated
from 52 countries across the world. Most were in Western higher-income countries: 38% in the United Kingdom and 28%
in the United States. Most registered trials reported as using qualitative methods evaluated behavioural (39%) or other
interventions with many fewer trials evaluating drugs (5%), medical devices (5%) or surgical interventions (4%).
Conclusion: The reported use of qualitative methods in registered trials has increased over time and worldwide. They are
reportedly more frequent in high-income countries and in trials of behavioural and other interventions. Trialists and other
stakeholders need to recognise the benefits of using qualitative methods in surgical, device and drug trials, and trials
conducted in poorer countries. Moreover, they should seriously consider using qualitative methods in these trials.
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Background
The added value of using qualitative research methods
within trials is widely recognised [1–6]. O’Cathain et al.
[1] identified 22 ways in which qualitative research could
benefit trials including: identifying and addressing re-
cruitment and retention issues [4], ensuring trial designs
are appropriate to the population and condition they are
addressing [7] and facilitating the interpretation and imple-
mentation of trial findings through understanding trial
context [8]. Qualitative methods can also assess whether
trial processes are appropriate [9]. These methods have in-
formed trial design and conduct, for example, by assessing
fidelity and uptake of interventions and how and why they
work or not [10, 11]. Randomised trials are the most appro-
priate design for robust evaluations of complex health inter-
ventions [12, 13]. However, they are not without criticism.
There are concerns that they neglect patient and profes-
sional input [14] and are insensitive to the health-care
context [15]. Critics see them as artificial constructs that
depart from the real world [16] and therefore, cannot
model health-care on the ground [17].
Hence, trialists have turned to complementary methods
to address these concerns. Methodological guidance
[18, 19] and mounting evidence of the added value con-
ferred by qualitative methods in trials [1, 3, 20, 21] have
led trialists increasingly to adopt a multi-method approach,
integrating quantitative and qualitative components. While
qualitative methods are increasingly used within trials, their
full potential is often not realised [22]. They have not al-
ways been well integrated into trial designs, which reduces
methodological rigour and transparency [3]. For example,
excluding qualitative methodologists from the design phase,
especially from the formulation of trial aims and objectives,
may create conflict between qualitative and quantitative
components. Poor integration at the design stage often
leads to poor reporting that obscures qualitative methods
and findings [22, 23]. To identify how to improve qualita-
tive methods within trials, it is important to analyse how
trials report the use of qualitative methods and whether
these have changed over time.
Previous reviews have reported when, where and how
qualitative methods are used within trials [3, 20]. Though
the reported numbers of trials employing qualitative
methods differ across reviews, they are consistently low
compared with the total number conducted and published.
The proportion of trials that have reported qualitative
methods varies from 1% in palliative care trials [20] to 30%
in trials of complex interventions [3]. The reviews also re-
veal that, though trials including qualitative methods are
conducted worldwide with multi-national authorships, they
are mainly within rich countries [3, 22]. However, these re-
views are essentially cross-sectional, encompassing a couple
of years, for example 2008–2010 [1]. Moreover, searches
cover only single registries or published trials. Furthermore,
these reviews have focused mainly on trials of complex
interventions that evaluated behavioural interventions
aimed at changing participants’ behaviour at the individual
or community level [20, 24]. More recently the term ‘com-
plex intervention’ has evolved to cover a wider range of
interventions, including surgical procedures, medical de-
vices and drugs. This reflects the increasing complexity of
clinical interventions [7, 19, 25]. It is, therefore, important
to subdivide these complex interventions from previous
reviews to characterise the trials that report qualitative
methods.
Depending on the country of the sponsor, clinical trials
are either required or encouraged to register prospect-
ively with a trials registry. These registries have been
established across the world to address concerns about
access to trials, publication bias and more recently, trial
results. In the United States, the Food and Drug Admin-
istration Modernization Act of 1997 and subsequent
amendments mandated the development of a registry
and registration of both federally funded and privately
funded trials, with penalties for non-compliance [26]. In
2004, the members of the International Committee of
Medical Journal Editors published an editorial promoting
the prospective registration of all clinical trials, leading to
the establishment of a trial registry within the United
Kingdom [27]. This was later supported by the World
Health Organisation (WHO), which promoted registration
further afield [28]. Registries aim to provide increased ac-
cess to information and transparency about trials for re-
searchers, clinicians, patients and members of the public.
These registries give access to information about each trial
provided by the trial team, including: lead researcher’s
name and organisation, study design including type of trial
and methods, and the organisation responsible for over-
seeing governance. In principle, they also report the extent
of qualitative methods within the trial.
This review is part of a larger project to characterise
best practice in conducting qualitative research within
trials. The objectives of this project are:
1 To describe the characteristics of trials reporting
the use of qualitative methods
2 To explore good practice in planning and running
clinical trials using qualitative methods
3 To explore the roles that participants play in
clinical trials using qualitative methods
4 To explore and identify potential facilitators of and
barriers to qualitative research within trials
5 To make recommendations for best practice for
using qualitative methods within trials.
This review builds on previous reviews by estimating
the frequency of the reported use of qualitative methods
in trials over 16 years, longer than previous reviews, and
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analysing trials that report using qualitative methods,
specifically the types of intervention evaluated and their
locations.
Methods
To assess the use of qualitative methods in trials, we
reviewed existing clinical trial registries and identified
trials that reported using qualitative methods, in four
main steps:
Step 1: We used internet search engines to identify
existing clinical trial registries. We included registries if:
they could be searched for keywords; they held records
of individual trials, not merely reports or publications;
and they held records in English. We searched all in-
cluded registries from the first available record, which
varied across registries, until 31 December 2016.
Step 2: We searched these registries for the keyword
‘qualitative’. The lead researcher (CC) reviewed all identi-
fied trials and extracted the following data into an Excel
spreadsheet: registry name (to allow comparison across
registries), registry record number (as a unique identifier),
trial title, year of first registration with registry, country re-
sponsible for overseeing governance of the trial (as many
trials recorded multiple recruiting countries, we chose the
most likely source of decisions about trial design) and type
of trial intervention (categorised as surgical, medical device,
drug, behavioural – which aimed to modify the behaviour
of individuals or communities – or other). We derived
these types from descriptions used by the registries, existing
literature and previous reports [22, 29, 30].
Step 3: We checked the registry records for docu-
mented use of qualitative methods. We defined these as
qualitative data collection (such as observation, interviews,
focus groups, documents or visual data), qualitative data
analysis (such as textual or visual) or both [31, 32].
Step 4: We analysed these data using the filter and
count features within Excel. We counted frequencies for:
number of registered trials reporting the use of qualitative
methods, year of first registration with registry, country
responsible for overseeing governance of the trial and type
of trial intervention as defined in Step 2. We presented
our findings as frequencies and percentages.
Results
Trial registries
Our search identified five main clinical trial registries:
ClinicalTrials.gov, WHO’s International Clinical Trial
Registry Platform (WHO ICTRP), the International Stand-
ard Randomised Controlled Trial Number (ISRCTN)
Registry, the Cochrane Central Register of Controlled Trials
(Cochrane CENTRAL) and the European Union Clinical
Trials Register. However, we excluded the last of these, as it
forms part of the WHO ICTRP, and Cochrane, as it is a
database of trial reports rather than a registry of trials.
Included registries
ClinicalTrials.gov
This registry was created in response to patient pressure
for access to information on clinical trials. It is run by
the United States National Library of Medicine within
the National Institutes of Health and claims to be the
largest clinical trials database in the world, registering
trials from 200 countries [30]. It records information on
federally, commercially and privately funded clinical trials,
including information on participant eligibility, locations
of trial activity, point of contact and, more recently, basic
results. US law enforces penalties for non-compliance with
this registry. Approximately 38% of the trials registered
within ClinicalTrials.gov are based only inside the US,
56% are based only outside the US and 5% are based in
both [30].
International Standard Randomised Controlled Trial
Number Registry
The ISRCTN registry contains basic data on all clinical
trials which have been assigned an ISRCTN number.
The registry is a not-for-profit organisation sponsored
by the Canadian Institute of Health Research, the Italian
Instituto di Ricerche Farnacologiche ‘Mario Negri’, the
Netherlands Organisation for Health Research and
Development, the UK Department of Health, and the
UK Medical Research Council. However, most of the
registered trials are based in the UK [33]. The ISRCTN is
a simple numeric system that facilitates the identification
and tracking of trials throughout their life cycle. The regis-
try uses the WHO 20-item Trial Registration Data Set
covering: study hypothesis, study design, countries of re-
cruitment, selection criteria, disease or condition, inter-
vention, sponsor and contact information [33].
World Health Organisation International Clinical Trials
Registry Platform
This registry also uses the WHO Trial Registration Data
Set. The portal provides access to 16 separate registries
from across the world [34], including ClinicalTrials.gov
and ISRCTN. Thus, we took care not to duplicate trials
from those registries.
Trials with confirmed use of qualitative methods
The three included registries recorded a total of 615,311
trials from their first record (occurring in 1999 for Clinical-
Trials.gov, 2004 for ISRCTN and 2006 for WHO ICTRP)
until 31 December 2016. The WHO ICTRP registry was
the largest with 366,753 trials registered, ClinicalTrials.gov
the second largest with 233,277 trials and ISRCTN the
smallest with 15,301 trials. Of these, 2477 records included
the keyword ‘qualitative’: 144 (0.03%) from WHO ICTRP,
1668 (0.7%) from ClinicalTrials.gov and 665 (4.6%) from
ISRCTN. Of these 2477 records, we confirmed that 1492
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(60.2%) trials had used qualitative methods. The main rea-
sons for excluding 985 records were: use of the term ‘quali-
tative’ to describe quality of life measures, to refer to
medical tests like ‘qualitative urine test or MRI imaging’ or
to cite statistical tests as ‘qualitative Fishers Exact Test’.
None of these fitted our criteria for qualitative methods.
Table 1 shows that ISRCTN contributed by far the
highest percentage of registered trials subsequently con-
firmed as using qualitative methods (3.4%). In contrast,
ClinicalTrials.gov had only 0.3%, and WHO ICTRP had
the smallest proportion at 0.03%.
Trials confirmed as using qualitative methods by year
registered
The number of registered trials increased over time from
1999, when first reported in ClinicalTrials.gov, to the end
of 2016. The number and percentage of these trials re-
ported as having used qualitative methods also increased
steadily over time across all registries (Figs. 1 and 2). The
year in which the first trial reported to use qualitative
methods was identified differed across the registries: 2000
in ISRCTN, 2001 in ClinicalTrials.gov and 2006 in WHO
ICTRP. As all registries held records of trials reported as
using qualitative methods from 2004, we compared the
number across time within each registry between 2004
and 2016. This revealed substantial increases across time
in all three registries: from 1.2% to 8.4% in ISRCTN, from
0.03% to 0.59% in ClinicalTrials.gov and from 0% to 0.06%
in WHO ICTRP.
Types of registered trials confirmed as using qualitative
methods
Of the 1492 registered trials confirmed as reporting the
use of qualitative methods, most were evaluating a be-
havioural intervention (39%) or an other intervention
that did not fit the defined categories, mainly vaccines,
nutritional supplements and diagnostic testing (47%). In
contrast, clinically orientated trials evaluating drugs (5%),
medical devices (5%) or surgical interventions (4%) were
much less likely to report the use of qualitative methods.
This was broadly consistent across the three trial registries
(Table 2).
Registered trials confirmed as using qualitative methods by
country
Trials with confirmed use of qualitative methods were
registered from 52 countries across the world. The high-
est number were registered in the UK (570 trials, 38.2%),
followed by the US (425 trials, 28.5%), Canada (71 trials,
4.6%), France (67 trials, 4.5%), Australia (43 trials, 2.9%),
Germany (37 trials, 2.5%) and Denmark (34 trials, 2.3%).
None of the remaining 45 countries accounted for more
than 2% of all confirmed qualitative trials.
We examined each registry for the country overseeing
most of the registered trials reported to use qualitative
methods. Most of the trials registered within ISRCTN
were conducted in the UK (444, 77.9%); 124 UK trials
(21.8%) were registered in ClinicalTrials.gov and two UK
trials in WHO ICTRP. Most of the trials within Clinical
Trials.gov were conducted in the US (419, 98.6%), with
six US trials (1.4%) in ISRCTN but no US trials (0%) in
WHO ICTRP. Most of the trials within WHO ICTRP
were conducted in Australia (36, 15.5%), with four
Australian trials (9.3%) in ClinicalTrials.gov and three
Australian trials (6.8%) in ISRCTN.
We classified countries by gross national income (GNI),
which was formerly known as gross domestic product
(GDP), as estimated by the World Bank Group using the
World Bank Atlas Method [35]. Most registered trials re-
ported to use qualitative methods were conducted in
high-income countries like the UK (570 trials, 38.2%) and
the US (425 trials, 28.5%). Low- and low-middle-income
countries had very few trials reported as using qualitative
methods, for example Uganda (four trials, 0.26%) and
Ethiopia (two trials, 0.13%) (Table 3). In all registries, most
of the trials that reported using qualitative methods were in
the high-income category. However, the distributions for
each category differ across registries: most of the trials
that reported using qualitative methods within low-in-
come or low-middle-income countries were registered
with ClinicalTrials.gov.
Discussion
Summary
This review has characterised trials registered on trial
registries and confirmed as using qualitative methods,
both across time (between 1999 and 2016) and across
Table 1 Registered trials using qualitative methods by registry
WHO ICTRP ClincalTrials.gov ISRCTN Overall
Total trials in registry from 1999 to 2016 366,753 233,277 15,301 615,311
Total identified with qualitative keyword 144 1668 665 2477
Total records excluded 46 790 149 985
Total confirmed with qualitative methods 98 878 516 1492
Percentage confirmed with qualitative methods 0.04% 0.4% 3.4% 0.2%
ICTRP International Clinical Trials Registry Platform, ISRCTN International Standard Randomised Controlled Trial Number Registry, WHO World Health Organisation
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countries. Only 1492 (0.24%) of the 615,311 registered
trials identified across the three included trial registries,
either completed or in progress, reported the use of
qualitative methods. Most of these were based in the US
or UK, rich Western counties where the number of trials
reported to use qualitative methods has increased stead-
ily over time. Most trials reporting the use of qualitative
methods investigated behavioural or other interventions,
while trials evaluating drugs, medical device or surgical
procedures each contributed fewer than 5% of registered
trials reported to use qualitative methods.
Interpretation
Our finding that reported use of qualitative methods is
rare amongst clinical registered trials is consistent with
O’Cathain et al. [22], who found that few published drug
or medical device trials employed qualitative methods.
Surgical trials are reputedly difficult to design and con-
duct, so until recently, surgeons resisted the use of ran-
domised trials [25]. Although the number of surgical
trials being conducted is increasing [25, 36], they face
challenges; in particular the beliefs and preferences of
participating surgeons threaten their equipoise, that is
whether they are genuinely uncertain about the effect-
iveness of a clinical intervention [37]. Many surgeons
prefer not to standardise interventions, which contrib-
utes to good trial design [38]. However, qualitative
methods can describe experiences and beliefs and help
in the understanding of complex phenomena. They can
explore factors affecting equipoise and how to overcome
these, and help to establish core outcomes and mini-
mum standards for interventions [7]. Hence, qualitative
Fig. 1 Number of registered trials confirmed as using qualitative methods by registry by year. ICTRP International Clinical Trials Registry Platform,
ISRCTN International Standard Randomised Controlled Trial Number Registry, WHO World Health Organisation
Fig. 2 Registered trials confirmed as using qualitative methods by registry by year. ICTRP International Clinical Trials Registry Platform, ISRCTN
International Standard Randomised Controlled Trial Number Registry, WHO World Health Organisation
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methods can describe surgical behaviour and explore re-
cruitment issues in surgical trials. For example, Donovan
and colleagues developed the Qualitative Recruitment
Intervention [4], which has been implemented in surgi-
cal trials [39]. However, qualitative methods remain rare
in clinical trials and research is needed to explore why.
As drug trials are better established, it is unclear why
they too rarely report qualitative methods. There is evi-
dence of the benefits of qualitative methods in drug trials,
for example in understanding, identifying and addressing
barriers to recruitment [4], and exploring equipoise [8]. As
medical devices are increasing in variety and complexity
[40], there is a strong case for evaluating their benefits and
harms through trials [41]. Such trials face similar issues to
surgical trials, including: when to initiate trials, when to as-
sess outcomes, the acceptability of the intervention, the
choice of outcome measures and how to implement devices
into routine practice [41]. Qualitative methods can help to
tease out these issues, especially by conceptualising core
outcomes [42], showing how medical devices are perceived
and integrated into existing practice [40], and exploring the
most appropriate trial design [1]. For example, a qualitative
consultation with key stakeholders, notably patients and
professionals, can illuminate decisions about: trial arms,
study outcomes (in particular, clinical versus patient re-
ported) and frequency of reporting.
It is important to consider why registered trials of be-
havioural interventions are more likely to report using
qualitative methods, as this could help to increase their
use in more clinical trials. One plausible explanation is
that qualitative research methods emerged from the behav-
iourally oriented social sciences and humanities. Such disci-
plines have generally avoided positivism, the dominant
epistemology in biomedical sciences, in favour of inter-
pretivism and constructionism to understand how and
why people behave the way they do [43]. Hence, using
qualitative methods may be more acceptable in trials
that evaluate behavioural interventions. So, advancing
the use of qualitative methods in other trials may de-
pend on convincing their researchers of the benefits of
the interpretivist approach. However, this hypothesis
needs careful investigation.
The continuing increase in reported use of qualitative
methods in registered trials may indicate increased aware-
ness of qualitative methods or of the potential benefits of
including them in trials. Publications that may have con-
tributed to this increase include the empirical work of
O’Cathain [1], Lewin [3] and Flemming [1, 3, 20] and guid-
ance on using qualitative methods in trials [1, 2, 22, 44, 45].
As these publications primarily addressed British trials, this
may account for the greater use of qualitative methods in
the UK and the UK-based ISRCTN registry.
Pragmatic randomised trials seek to evaluate interven-
tions in normal clinical practice and thus, allow more
clinical autonomy. This yields more insight into partici-
pants’ views and experiences during the trial and a more
representative picture of lived experiences and real prac-
tice [46]. Thus, more pragmatic trials are using qualita-
tive methods to characterise patient experiences and
clinical practice beyond the trial [1, 47]. Increased adop-
tion of pragmatic trials may also have increased the use
of qualitative methods.
This review has found that, though relatively few regis-
tered trials report using qualitative methods worldwide,
most of these are conducted within rich Western coun-
tries, consistent with previous reports [3, 22]. There have
been calls for more trials within poorer countries, which
have a greater potential to improve public health [48].
However, obstacles to such trials include: less capacity to
deliver trials, weaker links between trial conduct and
Table 2 Registered trials confirmed as using qualitative methods by type of intervention by registry
Type of trial intervention WHO ICTRP ClinicaTrial.gov ISRCTN Total
Other 75 (76.5%) 335 (38.2%) 289 (56.0%) 699 (46.9%)
Behavioural 20 (20.4%) 419 (47.7%) 147 (28.5%) 586 (39.3%)
Drug 2 (2%) 43 (4.9%) 37 (7.2%) 82 (5.5%)
Medical device 1 (1%) 54 (6.2%) 14 (2.7%) 69 (4.6%)
Surgical 0 (0%) 27 (3.1%) 29 (5.6%) 56 (3.8%)
ICTRP International Clinical Trials Registry Platform, ISRCTN International Standard Randomised Controlled Trial Number Registry, WHO World Health Organisation
Table 3 Registered trials confirmed as using qualitative methods by country income by registry
Country income category Gross national income WHO ICTRP ClinicalTrials.gov ISRCTN Total
Low $1005 or less 0 (0%) 14 (73.6%) 5 (26.3%) 19 (1.3%)
Low-middle $1006–$3955 2 (7%) 21 (72.4%) 6 (20.7%) 29 (1.9%)
Upper-middle $3956–$12,235 5 (11%) 41 (89.1%) 1 (2.17%) 47 (3.1%)
High $12,236 or more 91 (7%) 802 (57.4%) 504 (36.1%) 1397 (93.7%)
ICTRP International Clinical Trials Registry Platform, ISRCTN International Standard Randomised Controlled Trial Number Registry, WHO World Health Organisation
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current practice, and the need to adapt trials to local con-
text and culture. These issues make qualitative methods
even more challenging [48, 49]. Nevertheless, Vischer and
colleagues [48] have shown how qualitative methods can
address these issues in low-income countries. They inter-
viewed key informants in Burkina Faso, Ghana, Kenya and
Senegal to investigate factors slowing clinical trials. Trial
staff described factors apparently hindering trials, including
lack of planning and poor understanding of trial processes.
This generated recommendations for explicit trial planning
and site organisation [48]. Thus, qualitative methods can
improve the conduct of trials in poorer countries, such as
by consulting stakeholders, not least about cultural accept-
ability, for example of trial outcome measures. It is import-
ant, therefore, to test whether applying this approach more
widely can both increase the number of trials and the pro-
portion that use qualitative methods. It is also important to
disseminate such work through publication in international
journals and rigorous training.
Strengths, limitations and future directions
This review is limited to trials reported by researchers in
trial registries as using qualitative methods and confirmed
by inspecting their registry summaries. However, there may
be registered trials that use qualitative methods without
reporting this to the registry. Indeed, searching the three
registries for trials using the terms ‘interviews’, ‘focus groups’
or ‘mixed methods’ identified 8267 registered trials. We
checked a random 177 of these and found that 50 of their
registry summaries reported the use of qualitative methods.
Hence, the true number of clinical trials in these registries
using qualitative methods is closer to 3800 (0.62%). This
highlights two issues: Why did registries not check tri-
als a little more thoroughly for use of qualitative compo-
nents? How should registries identify trials with qualitative
methods in future? We recommend that, as more trials use
qualitative methods, trial registries should ask about quali-
tative methods within their application forms.
We did not address whether registries reported findings
or whether qualitative methods influenced trial processes,
outcomes or plans for implementation. With increasing
pressure on trials to report findings within registries, now
mandated within the US, it will soon be possible to see
whether trials report qualitative findings and, in particular,
whether they use qualitative methods to interpret findings
or alter trial design. It will also become important to
examine how registries apply those methods. Although
they collect similar data, they differ in how they register
trials and manage data, and above all in the proportion of
trials that report the use of qualitative methods.
This review reports on important characteristics of
registered trials that reported using qualitative methods,
namely: when they registered, where they were conducted
and the type of intervention they evaluated. Unfortunately,
information was limited and inconsistent about other
trial features, notably the design of the registered trials,
their use of qualitative methods, their phase, sample
sizes for both trials and their qualitative studies, trial
outcome measures (for example, the balance between
clinical and patient-reported), qualitative methods used,
and how these methods related to trial objectives. While
much of this information is available in the corresponding
peer-reviewed publications, extracting it is a major task, as
is analysing the relationship between these characteristics
and trials’ use of qualitative methods.
A strength of this review is the inclusion of all trials
registered between the start of 1999 and the end of
2016. This has shown a clearly increasing trajectory of
trials using qualitative methods. Previous reviews covered
shorter periods of time and could not analyse changes
over time [1, 3]. Including the three main international
registries has improved our understanding of when and
where trials are using qualitative methods.
Conclusion
This review has highlighted the increasingly reported
use of qualitative methods in registered trials over time
and across countries. However, these methods are more
prevalent in rich Western countries and in less clinically
orientated trials. Trialists and other stakeholders need to
recognise the benefits of using qualitative methods in
surgical, device and drug trials, and trials conducted in
poorer countries, and should seriously consider the use
of qualitative methods in these trials.
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